GlassScriptPhysician profile
Morgan Kuhn
NPI 1801559653
$15,859.25
in general payments reported to CMS, 2019-2025
48 companies · $3,240 in 2025
The $3,240 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,005 · 2023: $7,525 · 2024: $4,090 · 2025: $3,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Travel and Lodging: $931 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,753.79 |
| Travel and Lodging | $931.30 |
| Education | $169.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,354.67 | 2022-2025 | |
| Emd Serono, INC. | $1,471.97 | 2022-2025 | Mavenclad, Mavenclad |
| Livanova USA, INC. | $1,283.15 | 2023-2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $1,056.75 | 2023-2025 | Briviact, Nayzilam, Fintepla |
| Novartis Pharmaceuticals Corporation | $984.59 | 2022-2025 | |
| Sk Life Science, INC. | $920.11 | 2022-2025 | Xcopri |
| Acadia Pharmaceuticals INC | $833.87 | 2022-2025 | Nuplazid, Daybue |
| Teva Pharmaceuticals USA, INC. | $684.65 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Jazz Pharmaceuticals INC. | $523.70 | 2022-2024 | |
| Mdd US Operations, LLC | $520.78 | 2022-2025 | Gocovri, Gocovri, Apokyn |
| Genentech USA, INC. | $446.50 | 2023-2025 | Ocrevus, Enspryng |
| Eisai INC. | $433.00 | 2023-2025 | |
| Lilly USA, LLC | $417.14 | 2022-2025 | Emgality, Amyvid, Kisunla |
| Neurelis, INC. | $377.24 | 2022-2024 | Valtoco |
| Pfizer INC. | $332.75 | 2023-2025 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $266.23 | 2022-2025 | Xtampza |
| Otsuka America Pharmaceutical, INC. | $254.13 | 2023-2025 | Rexulti, Nuedexta |
| Genzyme Corporation | $247.28 | 2022-2023 | |
| Lundbeck LLC | $241.53 | 2023-2025 | Vyepti |
| Argenx US, INC. | $200.24 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Biogen, INC. | $171.60 | 2023-2025 | Tysabri, Vumerity |
| Tanabe Pharma America, INC. | $162.84 | 2023-2025 | Radicava |
| Neurocrine Biosciences, INC. | $145.59 | 2023-2024 | Ingrezza, Ongentys |
| Impel Pharmaceuticals INC. | $131.83 | 2023 | Trudhesa |
| Kyowa Kirin, INC. | $120.16 | 2022-2024 | Nourianz |
| Boston Scientific Corporation | $109.47 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $107.85 | 2022-2024 | Ultomiris |
| Vanda Pharmaceuticals INC. | $107.46 | 2025 | Ponvory |
| Amgen INC. | $100.07 | 2022-2024 | Uplizna, Aimovig |
| Celgene Corporation | $81.72 | 2023-2025 | Zeposia |
| Biohaven Pharmaceutical Holding Company LTD. | $79.44 | 2022 | |
| Janssen Biotech, INC. | $76.99 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $66.70 | 2022 | |
| Horizon Therapeutics Plc | $65.45 | 2023 | Uplizna |
| Merz Pharmaceuticals, LLC | $63.21 | 2023-2025 | Xeomin, Inbrija, Ampyra |
| Grifols USA, LLC | $50.04 | 2025 | Gamunex-C |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.18 | 2022 | |
| Acorda Therapeutics, INC | $38.34 | 2024 | Inbrija |
| Almatica Pharma LLC | $38.12 | 2022 | |
| Merck Sharp & Dohme LLC | $38.05 | 2023 | Belsomra |
| Ge Healthcare | $36.47 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $34.62 | 2022-2023 | Rytary |
| Scilex Pharmaceuticals INC. | $34.26 | 2022 | |
| Currax Pharmaceuticals LLC | $28.78 | 2023 | Onzetra Xsail |
| Alnylam Pharmaceuticals INC. | $24.70 | 2023 | Onpattro |
| Octapharma USA, INC. | $17.45 | 2023 | Panzyga |
| Radius Health, INC. | $16.72 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.86 | 2025 | Fasenra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Kuhn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.